tiprankstipranks
Cynata Therapeutics Limited (AU:CYP)
ASX:CYP

Cynata Therapeutics Limited (CYP) Income Statement

4 Followers

Cynata Therapeutics Limited Income Statement

Last quarter (Q4 2022), Cynata Therapeutics Limited's total revenue was AU$―, a decrease of ― from the same quarter last year. In Q4, Cynata Therapeutics Limited's net income was AU$―. See Cynata Therapeutics Limited’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Jun 22Jun 21Jun 20Jun 19Jun 18
Total Revenue
------
Cost of Revenue
------
Gross Profit
------
Operating Expense
-AU$ 13.84MAU$ 9.08MAU$ 10.51MAU$ 10.06MAU$ 6.13M
Operating Income
-AU$ -13.84MAU$ -9.08MAU$ -10.51MAU$ -10.06MAU$ -6.13M
Net Non Operating Interest Income Expense
-AU$ 64.75KAU$ 92.30KAU$ 142.35KAU$ 260.55KAU$ 142.93K
Other Income Expense
-AU$ 8.33MAU$ 1.30MAU$ 6.73MAU$ 1.33MAU$ 1.42M
Pretax Income
-AU$ -5.45MAU$ -7.69MAU$ -3.64MAU$ -8.47MAU$ -4.57M
Tax Provision
-AU$ 0.00AU$ 0.00AU$ 0.00AU$ 0.00AU$ 0.00
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
-AU$ -5.45MAU$ -7.69MAU$ -3.64MAU$ -8.47MAU$ -4.57M
Basic EPS
-AU$ -0.04AU$ -0.06AU$ -0.03AU$ -0.08-
Diluted EPS
-AU$ -0.04AU$ -0.06AU$ -0.03AU$ -0.08-
Basic Average Shares
-AU$ 143.28MAU$ 130.43MAU$ 104.82MAU$ 100.21M-
Diluted Average Shares
-AU$ 143.28MAU$ 130.43MAU$ 104.82MAU$ 100.21M-
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
------
Net Income From Continuing And Discontinued Operation
-AU$ -5.45MAU$ -7.69MAU$ -3.64MAU$ -8.47MAU$ -4.57M
Normalized Income
-AU$ -5.45MAU$ -7.69MAU$ -3.64MAU$ -8.47MAU$ -4.57M
Interest Expense
------
EBIT
-AU$ -13.84MAU$ -9.08MAU$ -10.51MAU$ -10.06MAU$ -6.13M
EBITDA
-AU$ -13.56MAU$ -8.80MAU$ -10.23MAU$ -9.78MAU$ -5.85M
Currency in AUD

Cynata Therapeutics Limited Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis